BioStem Technologies, Inc. · NASDAQ:BSEM
BioStem Technologies — Investor Presentation (March 2025)
31 slides from BioStem Technologies's investor presentation, March 2025
Slide 1: Investor Presentation March 2025
Investor Presentation March 2025
Slide 2: Forward Looking Statements
BIOSTEM TECHNOLOGIES Forward Looking Statements No money or other consideration is being solicited at this time via this communication and, if sent to BioStem Technologies, Inc. (the “Company”) will not be accepted will be promptly returned. A subscription for our securities will be made pursuant to
Slide 3: Mission Statement
ABOUT BIOSTEM TECHNOLOGIES Mission Statement BioStem is a commercial-stage company focused on the development, manufacture, and commercialization of innovative technologies for advanced wound care. The company’s mission is to be the global leader in regenerative healing through continuous innovation
Slide 4: Corporate Highlights and Key Statistics
Key Statistics KEY STATISTICS As of March 19, 2025 Corporate Highlights Symbol: • OTC: BSEM Commercial Stage Company Price: ® • $9.73 • Leveraging the Company’s proprietary BioREtain processing method, have 4 placental- derived allograft products on the market for advanced wound care healing Market
Slide 5: Industry Leading Proprietary Technology
Industry Leading Proprietary Technology
Slide 6: Leading Proprietary Technology: Products Powered by BioREtain
HIGHLIGHTS LEADING PROPRIETARY TECHNOLOGY Products Powered by BioREtain® Retaining more of the key BioStem’s Patented, Differentiated Process components of the amniotic ® tissue: • The six-step BioREtain process preserves the natural integrity of the amniotic tissue factors critical to the healing p
Slide 7: Patents and Intellectual Property
PATENTS Patents and Intellectual Property Pending Issued Total Placental Tissue 24 3 27 BioREtain 4 1 5 Auxocell 0 37 37 Total 28 41 69 Grouped • Tissue Mincing Apparatus (15) • Clotting (4) International • Systems and Methods for Processing Cells (22) • Joint (4) Pending Applications • Processing a
Slide 8: Regulatory Pathway Overview
FDA CLEARED Regulatory Pathway Overview Our Products Biologic Drugs Regulatory Pathway 361 351 Human Tissue When more than minimally When minimally manipulated (i.e., placental tissue) manipulated Indication for Use Homologous use* As indicated by clinical trial Manufacturing Process cGTP CGMP Regul
Slide 9: Product Portfolio & Manufacturing Process
Product Portfolio & Manufacturing Process
Slide 10: Differentiated Commercial Product Portfolio
POWERED BY BIORETAIN® PROCESSING TECHNOLOGY Differentiated Commercial Product Portfolio WOUND CARE OPTIC ✓ Placental Allograft ✓ Placental Allograft ✓ Placental Allograft ✓ Placental Allograft ✓ Retain all Native Layers ✓ Retain all Native Layers ✓ Retains only Amnion ✓ Retains only Amnion • Amnion
Slide 11: BioStem Product Segments
APPLICATION & REVENUE BioStem Product Segments BioStem Products Have Application Across the Full Spectrum of Private Patient Care Facilities Hospital Inpatient Through 2024, >95% of product sales occur in 3 sites of care Mobile Wound ▪ Private office Health Care Clinic ▪ Mobile Health ▪ Long-term Ca
Slide 12: Placental Donation Network & Allograft Process
PROPRIETARY PRODUCT DEVELOPMENT Placental Donation Network & Allograft Process Placental Donation Network Proprietary Technology 1 2 3 4 5 6 7 Expectant Mom Mom Consents to Delivery of Healthy Donated Placental Microbiology Testing Proprietary 4-Year Shelf-Stable Introduced To Donate and Baby in the
Slide 13: AATB Accredited, cGTP Manufacturing Facility
MANUFACTURING FACILITY AND CLEAN ROOMS AATB Accredited, cGTP Manufacturing Facility ® Vertically Integrated Manufacturing Facility: • 30+ Years of Allograft Processing Experience • 6,100 Sq/ft Manufacturing Facility • 1,500 Sq/ft ISO clean room space • Expanding to 3,000 Sq/ft ISO space in Q1 – ‘25
Slide 14: Exclusive Commercial and Distribution Partnership with Venture Medical
Exclusive Commercial and Distribution Partnership with Venture Medical
Slide 15: Exclusive Commercial and Distribution Partnership with Venture Medical
SALES & MARKETING Exclusive Commercial and Distribution Partnership with Venture Medical About Venture Medical • Industry Leader: Premier wound care distributor and service provider in the U.S. • Expert Salesforce: Extensive, wound healing-focused sales team • End-to-End Support: Full-service soluti
Slide 16: BioStem Technologies/Venture Medical Partnership
PARTNERSHIP BioStem Technologies/Venture Medical Partnership Who ost lesale Acquisition C Wholesale Acquisition Cost to Venture Medical BioStem: ▪ Product Development Marketing ▪ Manufacturing Medical Education Shared Services: Marketing New Products Medical Education Venture Medical: Product Develo
Slide 17: Clinical Trial Snapshot
Clinical Trial Snapshot
Slide 18: Multi-Center, Randomized Controlled Trials are Underway
CLINICAL STRATEGY SNAPSHOT Multi-Center, Randomized Controlled Trials are Underway Data Product Study Wound Type Study Design Primary Outcome Status Readout Diabetic Foot 60 Patients across 10 Sites BR-AC-DFU-101 Complete closure at 12 weeks In Process ~ Q1 ’26 AmnioWrap2 Ulcers NCT06511596 (Vendaje
Slide 19: AmnioWrap2 & Vendaje AC Comparison vs. Leading Competitor
CLINICAL STRATEGY SNAPSHOT AmnioWrap2 & Vendaje AC Comparison vs. Leading Competitor Number of Applications BioStem AC products outperform the leading competitor head-to-head • Required fewer applications • Achieved wound closure more quickly Treatment Days Increased cost-effectiveness BioStem Techn
Slide 20: Chronic Wound Healing Market & Emerging Growth Opportunities
Chronic Wound Healing Market & Emerging Growth Opportunities
Slide 21: Multi Billion Dollar Opportunity within the Chronic Wound Market
STEADY U.S. GROWTH OPPORTUNITY BioStem is Addressing a Multi Billion Dollar Opportunity within the Chronic Wound Market Prevalent Chronic Wound 19% Wound Types % of Market Cases Market Population Increase in Medicare is Aging Population by 2030 Pressure Ulcers 43% 2024: 7,082,263 2025: 7,164,943 +7M
Slide 22: Financial Performance & Strategic Growth Initiatives
Financial Performance & Strategic Growth Initiatives
Slide 23: Strong Revenue Growth Trend
TRANSFORMATIVE YEAR Strong Revenue Growth Trend Preliminary, Unaudited $45,000,000 $301,827,301 2024 Has Delivered Record Financial Performance $301,827,301 $40,000,000 $35,000,000 Record Reve nue $30,000,000 $25,000,000 $20,000,000 $16,700,000 $15,000,000 $6,900,000 $10,000,000 $4,400,000 $5,000,00
Slide 24: 2024 Financial Highlights
HIGHLIGHTS 2024 FINANCIAL HIGHLIGHTS Record Quarterly and 12-Month Results Record Q4 revenue of $102.9M (Preliminary) Fourth Quarter of 2024 12-Month Period of 2024 $ 102.9M PRELIMINAR Y $ 301.8M PRELIMINAR Y Transformative 12-Month revenue of $301.8M (Preliminary) REVENUE REVENUE AmnioWrap2 and Q1
Slide 25: Strategic Initiatives in Place for Sustained Revenue Growth
ADVANCING THROUGH CORE GROWTH INITIATIVES Strategic Initiatives in Place for Sustained Revenue Growth Growth Through Strong Revenue Strengthen Strategic Acquisitions Market Expansion Growth & Profitability Reimbursement ✓ Expecting to broaden ✓ Expecting sustained ✓ Broadening path for ✓ Focusing on
Slide 26: Nasdaq Uplisting Process is Underway
NASDAQ APPLICATION SUBMITTED Nasdaq Uplisting Process is Underway Company Meets Nasdaq Requirements Across Corporate, Shareholder, and Financial Management Appointment of Independent Directors to Board Successful Completion of Comprehensive Audits Form 10 Registration Filed With The SEC in Sept. 202
Slide 27: Management Team & Conclusion
Management Team & Conclusion
Slide 28: Management Team
ABOUT US Management Team Jason Matuszewski, LSSBB Andrew VanVurst, CTBS Michael Fortunato, CPA Sean McCarrey Wendy Weston, PhD, CTBS Chief Executive Officer Chief Operating Officer Chief Financial Officer Chief Commercial Officer Vice President of R&D BioStem Technologies, Inc. | Listed: BSEM 28
Slide 29: Board of Directors
ABOUT US Board of Directors Thomas Dugan Jason Matuszewski, LSSBB Brandon Poe Andrew VanVurst, CTBS Kenneth Warrington, Ph.D. Patrick Daly Chairman of the Board BioStem Technologies, Inc. | Listed: BSEM 29
Slide 30: We Manufacture Products That Change Lives
CONCLUSION Well-Positioned to Capitalize on Opportunities Within the Wound Care Market Expand Portfolio Reporting Working Towards Committed to of Superior Clinically Expanding Payor Revenue Products Leading Significant Data Coverage Growth and the Wound Care Over Competitors Profitability Industry W
Slide 31: Thank You.
Thank You. biostemtechnologies.com | info@biostemtech.com | (954) 380-8342
BioStem Technologies — Investor Presentation (March 2025) on 6ix